- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03189420
Glioma Microenvironment an Exploratory Study
September 27, 2023 updated by: Raquel Chacon Ruiz Martinez, Hospital Sirio-Libanes
Diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable.
Advances in genetic analysis revealed that molecular and epigenetic alterations predict patients´s overall survival and clinical outcome.
However, glioma tumorigenicity is not exclusively caused by its genetic alterations.
The crosstalk between tumor cells and the surrounding microenvironment plays a crucial role in modulating glioma growth and aggressiveness.
In this sense, to understand the tumor microenvironment would elucidate potential treatment alternatives.
The focus will be to evaluate myeloid cells and cytokines levels.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The proposal is to study gene expression and early epigenetic changes in myeloid cells from brain tumors and co-culture experiments.
Tough RNA-seq, ATAC-seg and subsequent analysis to monitor the differential gene expression through different time points followed by stimuli.
The study will compare the obtained results with sequencing data from microglia of full-fledged human tumor samples (glioblastoma and low grade gliomas).
Additionally it will evaluated the immunologic characteristic of the tumor through cytokines levels analysis (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-13, IFN-γ, TGF-β e IL-1ra).
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sao
-
São Paulo, Sao, Brazil, 01308060
- Hospital Sírio Libanês
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Patients aged between 18-65 years old diagnosed with glioblastoma or low grade glioma
Description
Inclusion Criteria:
- 18 - 65 years old with brain tumor
- Patients that will be submitted to brain tumor ressection
Exclusion Criteria:
- Chronic neurodegenerative and inflamatory diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Glioblastoma
Samples of brain tumor diagnosed as glioblastoma
|
The tumors will be resected in routine therapeutic surgeries
Other Names:
|
Low grade glioma
Samples of brain tumor diagnosed as low grade glioma
|
The tumors will be resected in routine therapeutic surgeries
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
gene expression changes
Time Frame: 2 years
|
Though RNA-seq, ATAC-seg and subsequent analysis we will be able to monitor the differential gene expression through different time points followed by stimuli.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cytokines expression
Time Frame: 2 years
|
will evaluate the immunologic characteristic of the tumor through cytokines levels analysis (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-13, IFN-γ, TGF-β e IL-1ra).
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Komori T. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8.
- Galatro TF, Vainchtein ID, Brouwer N, Boddeke EWGM, Eggen BJL. Isolation of Microglia and Immune Infiltrates from Mouse and Primate Central Nervous System. Methods Mol Biol. 2017;1559:333-342. doi: 10.1007/978-1-4939-6786-5_23.
- Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017 Mar 13;31(3):326-341. doi: 10.1016/j.ccell.2017.02.009.
- Chiorean R, Berindan-Neagoe I, Braicu C, Florian IS, Leucuta D, Crisan D, Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data. Cancer Biomark. 2014;14(2-3):185-94. doi: 10.3233/CBM-130310.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2016
Primary Completion (Estimated)
October 1, 2023
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
June 14, 2017
First Submitted That Met QC Criteria
June 14, 2017
First Posted (Actual)
June 16, 2017
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE 58310716.6.0000.5461
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma of Brain
-
Tilburg UniversityCompletedLow Grade Glioma of Brain | Anaplastic Glioma of BrainNetherlands
-
Neurological Associates of West Los AngelesEnrolling by invitationLow Grade Glioma of BrainUnited States
-
Crystal Mackall, MDNational Institutes of Health (NIH); California Institute for Regenerative... and other collaboratorsRecruitingGlioma of Spinal Cord | Glioma of BrainstemUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingGlioma | Glioma of Brain | Glioma of Spinal CordUnited States, Italy
-
University of Alabama at BirminghamNot yet recruitingRecurrent Malignant Glioma | Glioblastoma Multiforme of Brain | Anaplastic Astrocytoma of Brain | Gliosarcoma of BrainUnited States
-
Oliver Jonas, PhDRecruitingGlioblastoma | Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Astrocytoma of Brain | Grade III Glioma | Grade IV Glioma | Grade II Glioma | Oligodendroglioma of BrainUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Treovir, LLC; American Lebanese Syrian Associated...Not yet recruitingNeoplasms | Malignant Glioma of Brain | Glioblastoma Multiforme | High Grade Glioma | Giant Cell Glioblastoma | High-grade Glioma | Anaplastic Astrocytoma of Brain | Anaplastic GliomaUnited States
-
Children's Hospital Medical Center, CincinnatiNovartisCompletedGlioblastoma | Malignant Glioma of Brain | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brainstem Glioma | Bithalamic High Grade GliomaUnited States
Clinical Trials on Tumor resection
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
University Hospital, GenevaRecruiting
-
University Hospital, ToursInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedBrain Tumor, PrimaryFrance
-
The University of Texas Health Science Center at...National Cancer Institute (NCI)RecruitingLung NeoplasmUnited States
-
Menoufia UniversityActive, not recruitingBladder CancerEgypt
-
Sohag UniversityCompletedSpinal Cord Tumor
-
Mansoura UniversityUnknown
-
Shanghai General Hospital, Shanghai Jiao Tong University...Unknown
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, AdultUnited States, Belgium, Switzerland, Germany, Netherlands
-
Duke UniversityRecruitingAdvanced Breast CancerUnited States